Approaches to identify genetic variants that influence the risk for onset of fragile X-associated primary ovarian insufficiency (FXPOI): A preliminary study

Frontiers in Genetics

Volumn 5, Issue AUG, 2014, Pages

  Allen, Emily G ^a   Grus, Wendy E ^b   Narayan, Sarayu ^a   Espinel, Whitney ^a   Sherman, Stephanie L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Knome Inc   (United States)

Author keywords

Disorder; Epistasis; Menopause; Ovarian failure; Primary ovarian insufficiency; Repeat expansion

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN;

5' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; EPISTASIS; FEMALE; FRAGILE X SYNDROME; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; MENSTRUAL CYCLE; MOLECULAR GENETICS; OVARY INSUFFICIENCY; PILOT STUDY; POLYMERASE CHAIN REACTION; PREMATURE OVARIAN FAILURE; QUESTIONNAIRE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; WHOLE GENOME SEQUENCING;

EID: 84906282544     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00260     Document Type: Article

References (59)

1. Allen, E. G., He, W., Yadav-Shah, M., and Sherman, S. L. (2004). A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum. Genet. 114, 439-447. doi: 10.1007/s00439-004-1086-x
2. Allen, E. G., Sullivan, A. K., Marcus, M., Small, C., Dominguez, C., Epstein, M. P., et al. (2007). Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum. Reprod. 22, 2142-2152. doi: 10.1093/humrep/dem148
3. Allingham-Hawkins, D. J., Babul-Hirji, R., Chitayat, D., Holden, J. J., Yang, K. T., Lee, C., et al. (1999). Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study-preliminary data. Am. J. Med. Genet. 83, 322-325.
4. Altshuler, D. M., Gibbs, R. A., Peltonen, L., Altshuler, D. M., Gibbs, R. A., Peltonen, L., et al. (2010). Integrating common and rare genetic variation in diverse human populations. Nature 467, 52-58. doi: 10.1038/nature09298
5. Atsma, F., Bartelink, M. L., Grobbee, D. E., and van der Schouw, Y. T. (2006). Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 13, 265-279. doi: 10.1097/01.gme.0000218683.97338.ea
6. Baley, J., and Li, J. (2012). MicroRNAs and ovarian function. J. Ovarian Res. 5:8. doi: 10.1186/1757-2215-5-8
7. Bione, S., Benedetti, S., Goegan, M., Menditto, I., Marozzi, A., Ferrari, M., et al. (2006). Skewed X-chromosome inactivation is not associated with premature ovarian failure in a large cohort of Italian patients. Am. J. Med. Genet. A 140, 1349-1351. doi: 10.1002/ajmg.a.31312
8. Brown, W. T., Houck, G. E. Jr., Jeziorowska, A., Levinson, F. N., Ding, X., Dobkin, C., et al. (1993). Rapid fragile X carrier screening and prenatal diagnosis using a nonradioactive PCR test [published erratum appears in JAMA 1994 Jan 5;271(1):28]. J. Am. Med. Assoc. 270, 1569-1575. doi: 10.1001/jama.1993.03510130075034
9. Bussani, C., Papi, L., Sestini, R., Baldinotti, F., Bucciantini, S., Bruni, V., et al. (2004). Premature ovarian failure and fragile X premutation: a study on 45 women. Eur. J. Obstet. Gynecol. Reprod. Biol. 112, 189-191. doi: 10.1016/j.ejogrb.2003.06.003
10. Cronister, A., Teicher, J., Rohlfs, E. M., Donnenfeld, A., and Hallam, S. (2008). Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis. Obstet. Gynecol. 111, 596-601. doi: 10.1097/AOG.0b013e318163be0b
11. De Caro, J. J., Dominguez, C., and Sherman, S. L. (2008). Reproductive health of adolescent girls who carry the fmr1 premutation: expected phenotype based on current knowledge of fragile x-associated primary ovarian insufficiency. Ann. N.Y. Acad. Sci. 1135, 99-111. doi: 10.1196/annals.1429.029
12. Ennis, S., Ward, D., and Murray, A. (2006). Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. Eur. J. Hum. Genet. 14, 253-255. doi: 10.1038/sj.ejhg.5201510
13. Gallagher, J. C. (2007). Effect of early menopause on bone mineral density and fractures. Menopause 14, 567-571. doi: 10.1097/gme.0b013e31804c793d
14. Garcia-Alegria, E., Ibanez, B., Minguez, M., Poch, M., Valiente, A., Sanz-Parra, A., et al. (2007). Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models. RNA 13, 756-762. doi: 10.1261/rna.206307
15. Gonzalez-Perez, A., and Lopez-Bigas, N. (2011). Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am. J. Hum. Genet. 88, 440-449. doi: 10.1016/j.ajhg.2011.03.004
16. Hagerman, R. J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., et al. (2001). Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57, 127-130. doi: 10.1212/WNL.57.1.127
17. He, C., Kraft, P., Chen, C., Buring, J. E., Pare, G., Hankinson, S. E., et al. (2009). Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat. Genet. 41, 724-728. doi: 10.1038/ng.385
18. Hundscheid, R. D., Braat, D. D., Kiemeney, L. A., Smits, A. P., and Thomas, C. M. (2001). Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives. Hum. Reprod. 16, 457-462. doi: 10.1093/humrep/16.3.457
19. Hunter, J. E., Epstein, M. P., Tinker, S. W., Charen, K. H., and Sherman, S. L. (2008). Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity. Genet. Epidemiol. 32, 553-559. doi: 10.1002/gepi.20329
20. Jacobsen, B. K., Heuch, I., and Kvale, G. (2003). Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am. J. Epidemiol. 157, 923-929. doi: 10.1093/aje/kwg066
21. Janicki, S. C., and Schupf, N. (2010). Hormonal influences on cognition and risk for Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 10, 359-366. doi: 10.1007/s11910-010-0122-6
22. Jin, P., Duan, R., Qurashi, A., Qin, Y., Tian, D., Rosser, T. C., et al. (2007). Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a drosophila model of fragile X Tremor/Ataxia syndrome. Neuron 55, 556-564. doi: 10.1016/j.neuron.2007.07.020
23. Kalantaridou, S. N., Naka, K. K., Papanikolaou, E., Kazakos, N., Kravariti, M., Calis, K. A., et al. (2004). Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J. Clin. Endocrinol. Metab. 89, 3907-3913. doi: 10.1210/jc.2004-0015
24. Kenneson, A., Zhang, F., Hagedorn, C. H., and Warren, S. T. (2001). Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum. Mol. Genet 10, 1449-1454. doi: 10.1093/hmg/10.14.1449
25. Lu, C., Lin, L., Tan, H., Wu, H., Sherman, S. L., Gao, F., et al. (2012). Fragile X premutation RNA is sufficient to cause primary ovarian insufficiency in mice. Hum. Mol. Genet. 21, 5039-5047. doi: 10.1093/hmg/dds348
26. Mallolas, J., Duran, M., Sanchez, A., Jimenez, D., Castellvi-Bel, S., Rife, M., et al. (2001). Implications of the FMR1 gene in menopause: study of 147 Spanish women. Menopause 8, 106-110. doi: 10.1097/00042192-200103000-00005
27. Mandon-Pepin, B., Touraine, P., Kuttenn, F., Derbois, C., Rouxel, A., Matsuda, F., et al. (2008). Genetic investigation of four meiotic genes in women with premature ovarian failure. Eur. J. Endocrinol. 158, 107-115. doi: 10.1530/EJE-07-0400
28. Marozzi, A., Vegetti, W., Manfredini, E., Tibiletti, M. G., Testa, G., Crosignani, P. G., et al. (2000). Association between idiopathic premature ovarian failure and fragile X premutation. Hum. Reprod. 15, 197-202. doi: 10.1093/humrep/15.1.197
29. Meadows, K. L., Pettay, D., Newman, J., Hersey, J., Ashley, A. E., and Sherman, S. L. (1996). Survey of the fragile X syndrome and the fragile X E syndrome in a special education needs population. Am. J. Med. Genet. 64, 428-433.
30. Mondul, A. M., Rodriguez, C., Jacobs, E. J., and Calle, E. E. (2005). Age at natural menopause and cause-specific mortality. Am. J. Epidemiol. 162, 1089-1097. doi: 10.1093/aje/kwi324
31. Murray, A., Ennis, S., MacSwiney, F., Webb, J., and Morton, N. E. (2000). Reproductive and menstrual history of females with fragile X expansions. Eur. J. Hum. Genet. 8, 247-252. doi: 10.1038/sj.ejhg.5200451
32. Murray, A., Webb, J., Grimley, S., Conway, G., and Jacobs, P. (1998). Studies of FRAXA and FRAXE in women with premature ovarian failure. J. Med. Genet. 35, 637-640. doi: 10.1136/jmg.35.8.637
33. Newhall, K. J., Criniti, A. R., Cheah, C. S., Smith, K. C., Kafer, K. E., Burkart, A. D., et al. (2006). Dynamic anchoring of PKA is essential during oocyte maturation. Curr. Biol. 16, 321-327. doi: 10.1016/j.cub.2005.12.031
34. Nishimura, T., Sugiura, K., and Naito, K. (2013). A-kinase anchor protein 1 (AKAP1) regulates cAMP-dependent protein kinase (PKA) localization and is involved in meiotic maturation of porcine oocytes. Biol. Reprod. 88, 85. doi: 10.1095/biolreprod.112.106351
35. Peprah, E., He, W., Allen, E., Oliver, T., Boyne, A., and Sherman, S. L. (2010). Examination of FMR1 transcript and protein levels among 74 premutation carriers. J. Hum. Genet. 55, 66-68. doi: 10.1038/jhg.2009.121
36. Perry, J. R., Corre, T., Esko, T., Chasman, D. I., Fischer, K., Franceschini, N., et al. (2013). A genome-wide association study of early menopause and the combined impact of identified variants. Hum. Mol. Genet. 22, 1465-1472. doi: 10.1093/hmg/dds551
37. Rae, J. M., Johnson, M. D., Scheys, J. O., Cordero, K. E., Larios, J. M., and Lippman, M. E. (2005). GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res. Treat. 92, 141-149. doi: 10.1007/s10549-005-1483-4
38. Rodriguez-Revenga, L., Madrigal, I., Badenas, C., Xuncla, M., Jimenez, L., and Mila, M. (2009). Premature ovarian failure and fragile X female premutation carriers: no evidence for a skewed X-chromosome inactivation pattern. Menopause 16, 944-949. doi: 10.1097/gme.0b013e3181a06a37
39. Rohr, J., Allen, E. G., Charen, K., Giles, J., He, W., Dominguez, C., et al. (2008). Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum. Reprod. 23, 1220-1225. doi: 10.1093/humrep/den050
40. Schwartz, C. E., Dean, J., Howard-Peebles, P. N., Bugge, M., Mikkelsen, M., Tommerup, N., et al. (1994). Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am. J. Med. Genet. 51, 400-402. doi: 10.1002/ajmg.1320510419
41. Sellier, C., Freyermuth, F., Tabet, R., Tran, T., He, F., Ruffenach, F., et al. (2013). Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep. 3, 869-880. doi: 10.1016/j.celrep.2013.02.004
42. Sellier, C., Rau, F., Liu, Y., Tassone, F., Hukema, R. K., Gattoni, R., et al. (2010). Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J. 29, 1248-1261. doi: 10.1038/emboj.2010.21
43. Seltzer, M. M., Baker, M. W., Hong, J., Maenner, M., Greenberg, J., and Mandel, D. (2012). Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 589-597. doi: 10.1002/ajmg.b.32065
44. Shen, C., Delahanty, R. J., Gao, Y. T., Lu, W., Xiang, Y. B., Zheng, Y., et al. (2013). Evaluating GWAS-identified SNPs for age at natural menopause among chinese women. PLoS ONE 8:e58766. doi: 10.1371/journal.pone.0058766
45. Sherman, S. L. (2000). Seminars in genetics: premature ovarian failure in the fragile X syndrome. Am. J. Med. Genet. 97 189-195. doi: 10.1002/1096-8628(200023)97:3<189::AID-AJMG1036>3.0.CO;2-J
46. Siepel, A., Bejerano, G., Pedersen, J. S., Hinrichs, A. S., Hou, M., Rosenbloom, K., et al. (2005). Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 15, 1034-1050. doi: 10.1101/gr.3715005
47. Sofola, O. A., Jin, P., Qin, Y., Duan, R., Liu, H., De Haro, M., et al. (2007). RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 55, 565-571. doi: 10.1016/j.neuron.2007.07.021
48. Spath, M. A., Feuth, T. B., Allen, E. G., Smits, A. P., Yntema, H. G., van Kessel, A. G., et al. (2011a). Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers. Hum. Reprod. 26, 2185-2191. doi: 10.1093/humrep/der146
49. Spath, M. A., Feuth, T. B., Smits, A. P., Yntema, H. G., Braat, D. D., Thomas, C. M., et al. (2011b). Predictors and risk model development for menopausal age in fragile X premutation carriers. Genet. Med. 13, 643-650. doi: 10.1097/GIM.0b013e31821705e5
50. Spath, M. A., Nillesen, W. N., Smits, A. P., Feuth, T. B., Braat, D. D., van Kessel, A. G., et al. (2010). X chromosome inactivation does not define the development of premature ovarian failure in fragile X premutation carriers. Am. J. Med. Genet. A 152A, 387-393. doi: 10.1002/ajmg.a.33243
51. Stolk, L., Perry, J. R., Chasman, D. I., He, C., Mangino, M., Sulem, P., et al. (2012). Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat. Genet. 44, 260-268. doi: 10.1038/ng.1051
52. Stolk, L., Zhai, G., van Meurs, J. B., Verbiest, M. M., Visser, J. A., Estrada, K., et al. (2009). Loci at chromosomes 13, 19 and 20 influence age at natural menopause. Nat. Genet. 41, 645-647. doi: 10.1038/ng.387
53. Sullivan, A. K., Marcus, M., Epstein, M. P., Allen, E. G., Anido, A. E., Paquin, J. J., et al. (2005). Association of FMR1 repeat size with ovarian dysfunction. Hum. Reprod. 20, 402-412. doi: 10.1093/humrep/deh635
54. Sullivan, S. D., Welt, C., and Sherman, S. (2011). FMR1 and the continuum of primary ovarian insufficiency. Semin. Reprod. Med. 29, 299-307. doi: 10.1055/s-0031-1280915
55. Tassone, F., Beilina, A., Carosi, C., Albertosi, S., Bagni, C., Li, L., et al. (2007). Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA 13, 555-562. doi: 10.1261/rna.280807
56. Tejada, M. I., Garcia-Alegria, E., Bilbao, A., Martinez-Bouzas, C., Beristain, E., Poch, M., et al. (2008). Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome. Menopause 15, 945-949. doi: 10.1097/gme.0b013e3181647762
57. van der Stege, J. G., Groen, H., van Zadelhoff, S. J., Lambalk, C. B., Braat, D. D., van Kasteren, Y. M., et al. (2008). Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 15, 23-31. doi: 10.1097/gme.0b013e3180f6108c
58. Welt, C. K. (2008). Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin. Endocrinol. (Oxf.) 68, 499-509. doi: 10.1111/j.1365-2265.2007.03073.x
59. Welt, C. K., Smith, P. C., and Taylor, A. E. (2004). Evidence of early ovarian aging in fragile X premutation carriers. J. Clin. Endocrinol. Metab. 89, 4569-4574. doi: 10.1210/jc.2004-0347